This open-ended study was performed to compare the therapeutic effect and the clinical tolerability of a 5-day treatment with terconazole 0.8% cream with that of 6 days with clotrimazole 100-mg vaginal tablets. 75 patients on terconazole and 73 subjects on clotrimazole were studied, all of whom had positive cultures on Nickerson’s medium before treatment. Subjective symptoms and objective signs of vaginal candidosis and mycological findings were evaluated 1 and 4 weeks after completion of therapy. Before treatment, 92% of the patients in each treatment group had been suffering from pruritus, 77% from burning/irritation, and 96% from vaginal discharge. 1 week after completion of therapy, pruritus was present in 25%, burning/irritation in 23%, and vaginal discharge in 32% of the cases on terconazole. In the clotrimazole group, 15% had pruritus, 16% burning/irritation and 28% vaginal discharge. 4 weeks after completion of therapy, 15% of the subjects on terconazole had pruritus, 13% burning/irritation, and 18% vaginal discharge; in the clotrimazole group, the corresponding percentages were 12, 13 and 23%. Mycological cure rates at 1 week were 83% in the terconazole group and 89% in the clotrimazole group. 4 weeks after completion of therapy, 13% of the mycologically cured terconazole patients and 22% of the mycologically cured clotrimazole patients were positive again. Local treatment with terconazole was well tolerated by all patients, while 3 on clotrimazole complained of burning and pruritus. Of the 69 pregnant women treated, the status of mother and child at delivery was evaluated in 67. No drug-related abnormalities were noted.

Keywords:
Clotrimazole, Terconazole, Vaginal candidosis
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.